CEDAR KNOLLS, N.J., May 16 /PRNewswire-FirstCall/ -- Highlighting the
company's expectations for the future as well as its current product
pipeline, Michael V. Novinski, President and CEO of Emisphere Technologies,
Inc. (Nasdaq: EMIS), was featured in an extensive interview published
recently in The Wall Street Transcript (TWST). Established more than 40
years ago, TWST interviews the leaders of financial markets, including
CEOs, analysts and money managers, and publishes their viewpoints, opinions
and recommendations.
In his interview, Mr. Novinski discussed the two most important
objectives for the company moving forward: "We want to bring our technology
to the commercial level as soon as possible," he said, "and build our early
and mid-stage pipeline with additional partnerships, expecting to add three
new partnerships during 2008."
Mr. Novinski also explained Emisphere's proprietary eligen(R)
technology and its applications for drug delivery to address a number of
medical conditions. He said that the technology needs to come from the
clinical experimental stage to the commercial level. "At that point we will
be able to demonstrate that, in fact, our technology can provide benefits
to the population at large, for whatever treatment it is we are talking
about," Mr. Novinski explained.
One of those treatments is for Vitamin B12 deficiency. Emisphere has
completed two successful animal studies using its eligen(R) technology for
an oral formulation of Vitamin B12, and expects to be conducting studies in
humans by mid-year, Mr. Novinski told TWST. "We believe there should be an
opportunity to commercialize our technology [with our oral Vitamin B12
formulation] as early as next year."
Mr. Novinski also discussed the company's current partnerships,
highlighted by "two very exciting products with Novartis that are already
well into Phase III [development]." Through this program, "by the middle of
this year, more than 5,000 patients will be taking Emisphere's eligen(R)
technology with Salmon Calcitonin for the treatment of osteoarthritis and
osteoporosis," explained Mr. Novinski. "That's very exciting."
The entire Wall Street Transcript interview can be viewed at
Emisphere's Website, http://www.emisphere.com.
ABOUT EMISPHERE TECHNOLOGIES, INC.
Emisphere Technologies, Inc. is a biopharmaceutical company that
focuses on a unique and improved delivery of therapeutic molecules and
pharmaceutical compounds using its eligen(R) Technology. Some of these
molecules or compounds can only be given by injection; when combined with
our technology; convenient oral versions may be safe, effective and provide
significant advantages. The benefits of other compounds are limited due to
poor bioavailability, slow on-set of action or variable absorption. In
those cases, use of Emisphere's technology can improve the therapeutic
effectiveness of the compounds. The eligen(R) technology can be applied to
the oral route of administration as well other delivery pathways, such as
buccal, per rectum, pulmonary, intra-vaginal or transdermal. The web site
is: http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-Looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding potential third party
collaborations, future performance or financial results, the timing or
potential outcomes of research collaborations or clinical trials, any
market that might develop for any of Emisphere's product candidates and the
sufficiency of Emisphere's cash and other capital resources) are
forward-looking statements that involve risks and uncertainties, including,
but not limited to, the likelihood that one or more potential third party
collaborations may not be consummated, that actual performance or results
could materially differ, that future research will prove successful, the
likelihood that any product in the research pipeline will receive
regulatory approval in the United States or abroad, the ability of
Emisphere and/or its partners to develop, manufacture and commercialize
products using Emisphere's drug delivery technology, or Emisphere's ability
to fund such efforts with or without partners. Emisphere undertakes no
obligation to update any of these statements. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only
as to the date hereof. Accordingly any forward-looking statements should be
read in conjunction with the additional risks and uncertainties detailed in
Emisphere's filings with the Securities and Exchange Commission, including
those factors discussed under the caption "Risk Factors" in Emisphere's
Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, filed
on May 7, 2008.
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com/
CONTACT:
Bob Madison, Senior Director Corporate
Communications, +1-973-532-8001, bmadison@emisphere.com, or Adam
Friedman, Adam Friedman Associates, +1-212-981-2529, ext. 18,
adam@adam-friedman.com
|
